Publications

INX-315, an Oral, Potent and Selective CDK2 Inhibitor in Patients with CDK4/6 Inhibitor Resistant ER+/HER2-Breast Cancer or CCNE1 Amplified Solid Tumors

Antoinette R. Tan, MD, MHSc⁽¹⁾; Antonio Giordano, MD, PhD⁽²⁾; Catherine Shannon,
MD⁽³⁾; Carey Anders, MD⁽⁴⁾; Nashat Gabrail, MD⁽⁵⁾; Kevin Kalinsky, MD, MS⁽⁶⁾; Patrick
Roberts, PharmD, PhD⁽⁷⁾; Andrew Beelen, MD⁽⁷⁾; George Au-Yeung, MD, PhD⁽⁸⁾

⁽¹⁾Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, ⁽²⁾Dana-
Farber Cancer Institute, ⁽³⁾Mater Hospital, ⁽⁴⁾Duke Cancer Center, ⁽⁵⁾Gabrail Cancer Center
Research, (6)Emory Winship Cancer Institute, ⁽⁷⁾Incyclix Bio, LLC, ⁽⁸⁾Peter MacCallum Cancer Center

See the Publication >

INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors

Catherine Dietrich^1,2, Alec Trub³, Antonio Ahn^1,2, Michael Taylor^1,2, Krutika Ambani^1,2, Keefe T. Chan^1,2,
Kun-Hui Lu^1,2, Christabella A. Mahendra^1,2, Catherine Blyth^1,2, Rhiannon Coulson^1,2, Susanne Ramm^1,2,
April C. Watt^1,2, Sunil Kumar Matsa⁴, John Bisi³, Jay Strum³, Patrick Roberts³, and Shom Goel^1,2

Cancer Discov 2024;14:446–67

See the Publication >

INX-315, a potent and selective CDK2 inhibitor, demonstrates robust antitumor activity in CCNE1-amplified cancers

Alec G. Trub¹, John E. Bisi¹, Catherine Dietrich², Michael Taylor, Jay C. Strum¹, Shom Goel², Patrick J. Roberts^1
1Incyclix Bio, Durham, NC, United States, ²The Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

See the Publication >